Since Diniz and his collaborators (1961) first described a quantitative deter mination of kininogen levels in blood plasma,1 most of the studies on kininogen levels in the physiological and pathological conditions have been done by estimating total kininogen in human plasma. 2-10 Margolis (1963) was the first who reported that kininogen was not a single entity but included at least two substrates which possessed widely differing affinities for the releasing enzymes. He activated plasma kallikreinogen (Component A) to plasma kallikrein by contact with glass surface which in turn released plasma kinin from kininogen I (Component B). Total kininogen was measured by the kinin released with trypsin or urinary kallikrein. 11 There have since been other studies supporting the presence of two kininogens in the human blood plasma.12 According to Suzuki and collaborators, plasma kallikrein hydrolyzes only kininogen I. In this, it differs from glandular kallikrein and snake venom that digest both kininogens I and II. kinin were used as a stock solution of standard, which was diluted 100 times shortly before injection into the bath.
Comment on the methods Different names have been coined for the two kininogen components by authors who studied kininogen in blood plasma of mammals. Margolis gave the name Componet B to the substrate in plasma which released kinin by plasma kallikrein (activated Component A).11 Habermann et al.15 purified two kininogens of different molecular weight from bovine plasma and named these kininogens I and II, although they did not describe which one of them was susceptible to plasma kallikrein. Jacobsen,12,16 and Jacobsen and Kriz17 also purified two different kinino gens from human, dog and rabbit plasma and named them substrates 1 and 2. Sub strate 1 released the same amount of kinin when incubated with either plasma kallikrein or glandular kallikrein, while substrate 2 did not produce kinin through the action of plasma kallikrein. Suzuki and collaborators13 described separation of two different kininogens, kininogens I and II, from bovine plasma. They found that plasma kallikrein which was activated either by glass contact or by casein precipitation hydrolyzed only kininogen I which had a larger molecular weight than kininogen II. On the other hand, snake venom and glandular kallikrein released kinin from both of them.
The studies of Jacobsen and Suzuki are based on enzymological treatment in contrast to other investigations. In addition, both authors obtained so similar results that it seems reasonable to assume that substrates I and 2 of the former author are equal to kininogens I and II of the latter. The nomenclature of Suzuki is used in the present paper. Table 2 shows human plasma kininogen levels reported by various au thors.1, [3] [4] [5] 10, 11, 17, 18 In the papers of Margolis and Jacobsen, kininogen levels for plasma kallikrein were reported. Blood plasma contains kallikrein inhibitor which can inactivate plasma kallikrein before the substrate for the latter is used up. According to Werle,19 blood plasma of mammals contains about 1 to 5 K.I.U./ml of kallikrein inhibitor. For this reason, addition of exogenous plasma kallikrein is necessary to ensure hydrolysis of all kininogen I in the plasma. In the present study, 12 Frey units of human plasma kallikrein were used for one milliliter of plasma to overcome kallikrein inhibitor of plasma. The total kininogen level in the present method was in good accordance with that reported by Rinvik and by Brocklehurst. However, the kininogen I level was higher than that reported by Margolis and by Jacobsen. In the present study, all the kininogen levels are expressed in terms of bradykinin, because trypsin is used to release kinin from total kininogen and from kininogen II (kininogen I depleted substrate).
For the study of plasma kallikrein-kinin system, it seems essential to estimate the changes of kininogens I and II instead of total kininogen. The present method is sensitive enough for practical use in the simultaneous estimation of human plasma kininogens I and II.
